WALTHAM, Mass. (May 12, 2009) A new leadership team at IntrinsiQ today initiates a singular mission: to improve the quality of cancer care, by giving every stakeholder in the oncology field – physicians, nurses, pharmacists, practice managers, pharmaceutical researchers and managed care professionals – more clarity and insight into the clinical care process.
Led by Jeff Forringer, who becomes president after six years of successfully growing IntrinsiQ's pharmaceutical oncology consulting practice, IntrinsiQ's executive team now includes Rich Gray as division general manager of the IntelliDose® clinical software division, Mike Raquet as division general manager of the pharmaceutical data division, Steve Hamann as vice president of technology and Rob Weisman as director of finance.
To achieve this vision, the executive team will invest in new delivery models to increase the ease of deployment and accelerate practice-wide adoption of IntelliDose's full functionality. It will also give:
Deep and actionable insight for oncology practices into treatment decisions and clinical best-practices, as well as opportunities to improve workflow and profitability. The team will also continue to partner and interoperate with leading electronic medical record (EMR) providers to become the medical oncology module of choice.
Custom analysis of emerging clinical care trends for pharmaceutical clients to accurately interpret market factors that drive doctors' decisions, like statistically significant clinical research findings or removing reimbursement obstacles.
"Our goal is to give patients the best chance of beating the odds," said Forringer. "That's what happens when doctors make optimal treatment decisions, nurses correctly administer chemotherapy treatments and get more time to listen, and researchers bring to market new therapies and combinations that allow more patients to be treated – with better outcomes."
IntrinsiQ is considered oncology's leading source of real-time, real-world data for cancer treatment. Its analysis of 2 million drug administrations from more than 500 oncologists collected in IntelliDose each year helps everyone in the care spectrum identify the most effective treatments and emerging best practices.
Forringer's promotion to president culminates a 20-year career of building pharmaceutical information partnerships. One of the earliest members of the IntrinsiQ team, he grew IntrinsiQ's pharmaceutical data practice into researchers' go-to resource. Today, 28 of the top 30 global pharmaceutical companies are IntrinsiQ clients.
Gray returns to IntrinsiQ to lead the IntelliDose clinical software division. He brings more than 25 years of healthcare information technology experience working with companies like Meditech and MSM, Inc. Gray will tap his deep clinical experience as a registered pharmacist to manage sales, marketing, product management, and customer satisfaction teams.
Raquet spearheads pharmaceutical client service efforts to further the knowledge and understanding of oncology treatment. He brings 25 years of experience in every aspect of the pharmaceutical industry including clinical research, marketing, sales and manufacturing from senior-level positions at IMS Health, PRA International, and Tunnell Consulting.
Hamann is promoted to the management team following two years of spearheading a strategic roadmap to improve the user interface and underlying architecture of IntelliDose.
Weisman is promoted to director of finance after serving as IntrinsiQ's controller for two years. In previous positions, he served as controller at Sports Loyalty Systems and ISI Emerging Markets.
Gray, Raquet, Hamann and Weisman report to Forringer.
IntrinsiQ, LLC is the leading provider of medical oncology clinical information systems and the premier source of US oncology data and analysis. Each month, IntrinsiQ’s clinical software application, IntelliDose®, captures the treatment decisions and details from more than 500 oncologists, for nearly 20,000 unique patients, creating a database unrivaled in accuracy, detail and timeliness of information about the medical oncology care process. This database is the foundation of products and services that uniquely address the business information needs of pharmaceutical product managers, market researchers and financial analysts. For more information, please visit www.intrinsiq.com.